Skin

AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio

Retrieved on: 
Wednesday, May 1, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Mortality, FDA, Risk, ICS, Death, Weight loss, Growth, Gastrointestinal tract, Rash, TSLP, Formoterol, Biopharmaceutical, AstraZeneca, LABA, Inflammation, Salbutamol, Skin, Tezepelumab, Approval, EGPA, AMG, Allergy, Polyp (medicine), Bronchitis, Chronic obstructive pulmonary disease, Patient, Eosinophilic, Sinusitis, Rheumatology, Heart, Atmosphere, Fatigue, Immunology, Budesonide, Lung, Chronic pain, Asthma, COPD, Gastroenterology, Emphysema, Disease, Science, Conditional sentence, Dermatology, Pharmaceutical industry

In addition, we are also collaborating with AstraZeneca on AMG104/AZD8630, an inhaled anti-TSLP compound currently in development for asthma.

Key Points: 
  • In addition, we are also collaborating with AstraZeneca on AMG104/AZD8630, an inhaled anti-TSLP compound currently in development for asthma.
  • Respiratory & Immunology, part of BioPharmaceuticals, is one of AstraZeneca’s main disease areas and is a key growth driver for the Company.
  • With common pathways and underlying disease drivers across respiratory and immunology, AstraZeneca is following the science from chronic lung diseases to immunology-driven disease areas.
  • AstraZeneca’s ambition in Respiratory & Immunology is to achieve disease modification and durable remission for millions of patients worldwide.

MMI Completes First Symani® Clinical Cases in the U.S. Following FDA Commercial Authorization

Retrieved on: 
Wednesday, May 1, 2024
Technology, Surgery, Medical Devices, FDA, Hospitals, Hardware, Health, Robotics, Oncology, Leg, Microsurgery, Knee, Blood, Risk, Skin, Food, Hospital, Injury, Orthopedic surgery, Surgeon, Amputation, Patient, Multimedia, Platform supply vessel, Penn Presbyterian Medical Center, Classification, Quality of life, Forearm, Dentistry

Both robotic-assisted microsurgical procedures were performed at the Department of Orthopaedic Surgery at Penn Presbyterian Medical Center.

Key Points: 
  • Both robotic-assisted microsurgical procedures were performed at the Department of Orthopaedic Surgery at Penn Presbyterian Medical Center.
  • View the full release here: https://www.businesswire.com/news/home/20240501137865/en/
    The Symani® Surgical System: A first-of-its kind robotic technology that uniquely addresses the scale and complexities of microsurgery.
  • The surgical team revascularized the bone segment using the microsurgical robot to reconnect the tiny blood vessels and facilitate successful transfer.
  • To learn more about MMI and the Symani Surgical System, visit MMI’s website here: https://mmimicro.com .

Naples Soap Company to Launch New Sensitive Skincare Line for High Demand $41 Billion Market

Retrieved on: 
Tuesday, April 30, 2024
Pharmaceutical, Other Retail, Health, Vitamins, Supplements, Fitness & Nutrition, Cosmetics, Retail, Other Health, Dermatitis, American Academy, Self-care, Pharmacy, Skin, OTCQB, Cleveland Clinic, Skin care, DNA, Dermatology, Psoriasis, Rosacea, Multimedia, Beauty, Aloe vera, Coconut oil

The Grow Beautii line is set to serve an unmet segment of the rapidly growing $41 billion global sensitive skin care products market.

Key Points: 
  • The Grow Beautii line is set to serve an unmet segment of the rapidly growing $41 billion global sensitive skin care products market.
  • View the full release here: https://www.businesswire.com/news/home/20240430706613/en/
    Grow Beautii, a new line of skin care products formulated and designed specifically for users with sensitive skin is slated to launch in the fourth quarter of 2024.
  • “Creating self care and beauty products for sensitive skin is in our DNA at Naples Soap Company.
  • This personal journey is what inspired me to create and grow my own skin care line,” said Deanna Wallin, Founder & CEO of Naples Soap Company.

Bubble Skincare Announces Collaboration with Disney and Pixar’s Inside Out 2

Retrieved on: 
Wednesday, May 1, 2024
Packaging, Family, Other Entertainment, Consumer, Other Retail, Teens, Film & Motion Pictures, Manufacturing, Parenting, Children, Specialty, Fashion, Entertainment, Cosmetics, Retail, General Entertainment, Catalog, Other Education, Education, Online Retail, Women, Men, Cream, The Walt Disney Company, Skin, EVP, Collection, Emotion, Inside Out (2015 film), Human, History, Multimedia, Anxiety, Ulta

Bubble Skincare, the community-driven brand democratizing premium quality and highly effective skincare, announced today its first-ever brand collaboration, with Disney and Pixar’s Inside Out 2, which opens exclusively in theaters beginning June 14.

Key Points: 
  • Bubble Skincare, the community-driven brand democratizing premium quality and highly effective skincare, announced today its first-ever brand collaboration, with Disney and Pixar’s Inside Out 2, which opens exclusively in theaters beginning June 14.
  • Designed to help you “Face Your Feels,” the limited-edition Bubble Skincare x Disney and Pixar’s Inside Out 2 program highlights the effects that your emotions have on your skin (and vice versa).
  • “We are so excited to introduce our collaboration with Disney and Pixar’s Inside Out 2.
  • Beginning Wednesday, May 1, the Bubble Skincare x Disney and Pixar’s Inside Out 2 collaboration will be available for purchase on HelloBubble.com, Ulta.com and Walmart.com and will enter Ulta and Walmart stores nationwide in May and June, while supplies last.

Leading Brands Unveil Exclusive Offers for Verified Military Members During National Military Appreciation Month

Retrieved on: 
Tuesday, April 30, 2024
Technology, Marketing, Advertising, Communications, Specialty, Defense, Military, Fashion, Cosmetics, Home Goods, Retail, Vacation, Other Travel, Electronic Commerce, Travel, Digital Marketing, Veterans, Content Marketing, Software, Online Retail, Internet, Data Management, Other Retail, Tiny Love, Firefighter, Maytag, Clinique, Sale, CMO, L.L.Bean, Spouse, Safety, Woman, Skin, GAF, Codecademy, Commerce, Australian Defence Force, WWII, Research, Life, University, First responder, Military personnel, UGG, Dorel Industries, Whirlpool, Alterra Mountain Company, Canadian Armed Forces, Aveda, Holland America Line, Purple, EdX, United States Armed Forces, Epic, Evenflo, KitchenAid, Fireworks

SheerID, the global leader in identity verification for commerce, is partnering with 31 distinguished brands in 9 categories offering exclusive discounts to honor the millions of active military service members and veterans during National Military Appreciation Month this May.

Key Points: 
  • SheerID, the global leader in identity verification for commerce, is partnering with 31 distinguished brands in 9 categories offering exclusive discounts to honor the millions of active military service members and veterans during National Military Appreciation Month this May.
  • “At SheerID, we take immense pride in empowering brands to recognize and honor the invaluable contributions of military members and their families,” stated Sai Koppala, CMO of SheerID.
  • CheapCaribbean Vacations : Members of the military can join our Waves4Warriors Club and get $150 off their next beach vacation!
  • VIVAIA : As a thank you for their work and service, military members can enjoy an exclusive 20% off discount for the month of May.

Dermavant Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

Retrieved on: 
Monday, April 29, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Clinical Trials, Other Health, Dermatitis, Itch, Pain, Shanda, Skin, Inflammation, Food, Swelling, Stinger, Rash, Body surface area, Nose, Agency, Atopic dermatitis, Folliculitis, Common, Therapy, PDUFA, Incidence, Patient, Psoriasis, Red, Headache, Irritation, Ageing, Pharmaceutical industry

The Prescription Drug User Fee Act ("PDUFA") action date assigned by the Agency is in Q4 2024.

Key Points: 
  • The Prescription Drug User Fee Act ("PDUFA") action date assigned by the Agency is in Q4 2024.
  • VTAMA cream is a novel, aryl hydrocarbon receptor agonist in development as a once-daily, cosmetically elegant, and steroid-free, topical cream for both acute treatment and long-term management of AD.
  • On May 24, 2022, Dermavant announced the FDA approved VTAMA® (tapinarof) cream, 1% for the treatment of plaque psoriasis in adults.
  • Indication: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults.

Fact vs. Fiction: Debunking Common Misconceptions about Skin Cancer, Sun Safety

Retrieved on: 
Tuesday, April 30, 2024
Cancer, System, Risk, Skin, UVB, American Cancer Society, Sunburn, Skin cancer, Tanning, History, Disease, ACS, Eye, Nail, Melanoma, Death, Lip, SPF, Human, UV, Prevalence, Cosmetics

ATLANTA, April 30, 2024 /PRNewswire/ -- In the United States, more than 5 million cases of skin cancers are diagnosed each year. Despite its prevalence, there are still a number of misconceptions surrounding the disease. For Skin Cancer Awareness Month this May, the American Cancer Society (ACS) and Dr. Shanthi Sivendran, senior vice president, cancer care support at ACS, are sharing the facts behind some of these common fictions related to skin cancer and sun safety.

Key Points: 
  • For Skin Cancer Awareness Month this May, the American Cancer Society (ACS) and Dr. Shanthi Sivendran, senior vice president, cancer care support at ACS, are sharing the facts behind some of these common fictions related to skin cancer and sun safety.
  • FICTION: Skin cancer is relatively rare, and not many people in the U.S. are diagnosed with skin cancer.
  • While roughly 8 out of 10 new skin cancer cases are basal cell cancers, ACS estimates that about 100,640 new cases of melanoma skin cancer will be diagnosed in 2024.
  • Though melanoma accounts for only about 1% of skin cancers, it is responsible for the large majority of skin cancer deaths.

'The Kerasal Cares FootCare Campaign' Rewarding Hardworking Feet

Retrieved on: 
Tuesday, April 30, 2024
Skin, Comment, Foot, Friends, Nail, Ageing, Auction

BRIDGEWATER, N.J., April 30, 2024 /PRNewswire/ -- In honor of April's National Foot Health Awareness Month, Kerasal, a leading brand of high-quality footcare products, launched The Kerasal Cares Footcare Campaign. Kerasal recognizes the important role foot health plays in our overall wellbeing and wants to reward those hardworking feet. The campaign offers individuals a chance to win footcare packages with a range of products designed to soothe, renew, and refresh feet after a long day.

Key Points: 
  • BRIDGEWATER, N.J., April 30, 2024 /PRNewswire/ -- In honor of April's National Foot Health Awareness Month, Kerasal , a leading brand of high-quality footcare products, launched The Kerasal Cares Footcare Campaign.
  • Kerasal recognizes the important role foot health plays in our overall wellbeing and wants to reward those hardworking feet.
  • If you have hardworking feet – put your best foot forward—and enter The Kerasal Cares Footcare Campaign.
  • Each week, Kerasal announces three winners and awards them with Kerasal Cares Gift Packages, filled with Kerasal products and valued at $100.

Parks! America Responds to FC Open Letter of April 2, 2024

Retrieved on: 
Thursday, April 11, 2024
Neglect, Senior management, Skin, Burn, Management, Giraffe, PINE, Water, Growth, Podcast, Cedar Fair, FC, Annual general meeting, Human, Meaningless, Person

America” or the “Company”) to the press release published by Focused Compounding, LLC (“FC”) in their open letter dated April 2, 2024.

Key Points: 
  • America” or the “Company”) to the press release published by Focused Compounding, LLC (“FC”) in their open letter dated April 2, 2024.
  • We do not see a shred of experience or industry knowledge in the group proposed by FC.
  • Is the Meaningless Special Meeting that FC forced upon the Company on February 26, 2024 an indication of FC’s competence?
  • Most importantly, if FC denies they want to bring back Mr. Van Voorhis, who it is that FC intends to have manage the Company?

Nanophase Announces Successful Litigation Settlement

Retrieved on: 
Thursday, April 11, 2024
Sale, Vexatious litigation, Prejudice, Skin, OTCQB, BASF, Partnership, Active ingredient, API, Beauty, Superior court, Pharmaceutical industry

The parties have executed a Settlement Agreement, an amendment to their existing supply contract, and a joint stipulation to dismiss the case with prejudice to be filed in the Superior Court of New Jersey within the next five business days.

Key Points: 
  • The parties have executed a Settlement Agreement, an amendment to their existing supply contract, and a joint stipulation to dismiss the case with prejudice to be filed in the Superior Court of New Jersey within the next five business days.
  • “We are happy to conclude this litigation on positive terms.
  • BASF has been a good partner to Nanophase over the years, and we expect that partnership to continue to bear fruit in the future,” said Nanophase President and Chief Executive Officer, Jess Jankowski.
  • Completion of the settlement allows Nanophase and Solésence to focus on what we do best, while continuing to support our sale of mineral-based Active Pharmaceutical Ingredients (“API”), into a market that recognizes the benefits these solutions bring,” continued Jankowski.